[
  {
    "ts": null,
    "headline": "11 Cheap Stocks for a Market That’s Too Expensive",
    "summary": "Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here’s how they did it and what they found.",
    "url": "https://finnhub.io/api/news?id=2a7eae537ad0a1d045f36b48be95d7adfc0d70ff89c7301f7c6304ec11d29ee3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759852140,
      "headline": "11 Cheap Stocks for a Market That’s Too Expensive",
      "id": 137002905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here’s how they did it and what they found.",
      "url": "https://finnhub.io/api/news?id=2a7eae537ad0a1d045f36b48be95d7adfc0d70ff89c7301f7c6304ec11d29ee3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval",
    "summary": "Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a key FDA approval for Evkeeza have put the company’s innovation and growth story back in the spotlight. See our latest analysis for Regeneron Pharmaceuticals. Regeneron’s streak of positive clinical updates and an FDA nod for Evkeeza are giving new life to its growth narrative. However, recent headlines around a one-off R&D charge led to a dip in shares last week. Over...",
    "url": "https://finnhub.io/api/news?id=ad0e2115688f663648e998ef511dac8cd38f175362302ae3d44d1b0984c84cf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759843201,
      "headline": "Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval",
      "id": 136999388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a key FDA approval for Evkeeza have put the company’s innovation and growth story back in the spotlight. See our latest analysis for Regeneron Pharmaceuticals. Regeneron’s streak of positive clinical updates and an FDA nod for Evkeeza are giving new life to its growth narrative. However, recent headlines around a one-off R&D charge led to a dip in shares last week. Over...",
      "url": "https://finnhub.io/api/news?id=ad0e2115688f663648e998ef511dac8cd38f175362302ae3d44d1b0984c84cf1"
    }
  }
]